Poltreg S.A. (PTG.WA)
PLN 35.0
(4.17%)
PLN 35.0
(4.17%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 127.09 Million PLN | 3.07% |
| 2022 | 123.3 Million PLN | 12.99% |
| 2021 | 109.12 Million PLN | 571.84% |
| 2020 | 16.24 Million PLN | 137.3% |
| 2019 | 6.84 Million PLN | -34.59% |
| 2018 | 10.46 Million PLN | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 112.44 Million PLN | -4.8% |
| 2024 Q1 | 118.11 Million PLN | -7.07% |
| 2023 Q1 | 128.66 Million PLN | 4.35% |
| 2023 FY | 127.09 Million PLN | 3.07% |
| 2023 Q2 | 122.58 Million PLN | -4.73% |
| 2023 Q4 | 127.09 Million PLN | -4.89% |
| 2023 Q3 | 133.62 Million PLN | 9.01% |
| 2022 Q2 | 112.79 Million PLN | 1.9% |
| 2022 Q1 | 110.68 Million PLN | 1.43% |
| 2022 Q3 | 120.44 Million PLN | 6.79% |
| 2022 FY | 123.3 Million PLN | 12.99% |
| 2022 Q4 | 123.3 Million PLN | 2.37% |
| 2021 Q1 | 17.61 Million PLN | 8.45% |
| 2021 Q4 | 109.12 Million PLN | 574.66% |
| 2021 Q3 | 16.17 Million PLN | -6.24% |
| 2021 FY | 109.12 Million PLN | 571.84% |
| 2021 Q2 | 17.25 Million PLN | -2.07% |
| 2020 Q4 | 16.24 Million PLN | 0.0% |
| 2020 FY | 16.24 Million PLN | 137.3% |
| 2020 Q1 | - PLN | 0.0% |
| 2019 FY | 6.84 Million PLN | -34.59% |
| 2018 FY | 10.46 Million PLN | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Bioceltix S.A. | 12.73 Million PLN | -897.998% |
| BIOTON S.A. | 822.22 Million PLN | 84.542% |
| Captor Therapeutics Spolka Akcyjna | 97.29 Million PLN | -30.633% |
| Mabion S.A. | 208.25 Million PLN | 38.97% |
| Molecure S.A. | 168.57 Million PLN | 24.606% |
| NanoGroup S.A. | 8.63 Million PLN | -1372.476% |
| Pharmena S.A. | 24.13 Million PLN | -426.678% |
| Pure Biologics Spólka Akcyjna | 22.73 Million PLN | -458.967% |
| Ryvu Therapeutics S.A. | 403.2 Million PLN | 68.478% |
| Synthaverse S.A. | 265.9 Million PLN | 52.201% |
| Urteste S.A. | 29.59 Million PLN | -329.414% |